Effects of Ibudilast (MN-166, Formerly AV411), a Glial Activation Inhibitor, on Oxycodone Self-administration in Opioid Abusers

Trial Profile

Effects of Ibudilast (MN-166, Formerly AV411), a Glial Activation Inhibitor, on Oxycodone Self-administration in Opioid Abusers

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Ibudilast (Primary)
  • Indications Opioid abuse
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Mar 2016 Results published in MediciNiva media release.
    • 07 Feb 2016 According to a MediciNova media release, data from this trial will be presented at the Behavior, Biology and Chemistry Annual Meeting and Symposium 2016.
    • 07 Feb 2016 According to a MediciNova media release, status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top